•Adverum reports 5-year extension data on wet AMD gene therapy•FDA forms advisory committee to review Sydnexis's low-dose atropine•Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles•Researchers identify higher post-cataract TED risk in patients with thyroid disease•Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop •Adverum reports 5-year extension data on wet AMD gene therapy•FDA forms advisory committee to review Sydnexis's low-dose atropine•Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles•Researchers identify higher post-cataract TED risk in patients with thyroid disease•Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop
HEADLINES
FEATURED
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
